Galecto, Inc. Sample Contracts
GALECTO, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • New York
GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt SecuritiesIndenture • November 4th, 2021 • Galecto, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [●], among GALECTO, INC., a corporation existing under the laws of the State of Delaware (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 4th, 2021 • Galecto, Inc. • Pharmaceutical preparations • New York
Galecto, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
GALECTO, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc, a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).
GALECTO, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 25th day of September, 2020, by and among Galecto, Inc., a Delaware corporation (the “Company”), and each of the stockholders listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
October 7, 2024Retention Compensation Agreement • March 19th, 2025 • Galecto, Inc. • Pharmaceutical preparations • Massachusetts
As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation as specified below, subject to this “Agreement”:
Employment Contract Galecto Biotech ApS and Bertil E. LindmarkEmployment Contract • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
Retention AgreementRetention Agreement • March 19th, 2025 • Galecto, Inc. • Pharmaceutical preparations
have today entered into this Retention Agreement (the "Retention Agreement") relating to the service agreement between the Parties, dated 23 April 2013 (the “Service Agreement”).
AGREEMENT AND PLAN OF MERGER by and among: GALECTO, INC., a Delaware corporation; DAYLIGHT MERGER SUB I, INC., a Delaware corporation; DAYLIGHT MERGER SUB II, LLC, a Delaware limited liability company; and DAMORA THERAPEUTICS, INC., a Delaware...Merger Agreement • November 10th, 2025 • Galecto, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of November 10, 2025, by and among GALECTO, INC., a Delaware corporation (“Parent”), DAYLIGHT MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), DAYLIGHT MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and DAMORA THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 10th, 2025 • Galecto, Inc. • Pharmaceutical preparations • Delaware
SERVICE AGREEMENT March 2013Service Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
Addendum to the Employment Contract Galecto Biotech ApS CVR no. 34 87 83 66 Ole Maal0es Vej 3 DK-2200 Copenhagen (the “Company’’) and Anders H. Pedersen (the “Employee’’) (each a “Party” and jointly the “Parties”) have today entered into this addendum...Employment Contract • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
ContractLease Agreement • March 19th, 2025 • Galecto, Inc. • Pharmaceutical preparations
English Summary of a lease agreement dated November 11, 2024 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and Symbion A/S (the “Landlord”)
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
This amendment to the Employment Agreement of Jonathan Freve is made and entered into between Galecto, Inc. (the “Company”), and Jonathan Freve, (the “Employee” or “You”), (together, the “Parties”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMITTED INFORMATION HAS BEEN REPLACED BY ASTERISKSBonus Agreement • November 6th, 2023 • Galecto, Inc. • Pharmaceutical preparations
have today entered into this retention bonus agreement (the "Bonus Agreement") relating to the service agreement between the Parties, dated 23 April 2013 (the “Service Agreement”).
English Summary of a lease agreement dated May 4, 2020 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and COBIS A/S (the “Landlord”)Lease Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations
• Modifications to leased Premises: Galecto is permitted to effect modifications to the leased premises only with the prior written approval of the Landlord. Galecto and the Landlord will agree on the costs, reimbursement and potential obligations to build-back modifications.
September 26, 2023 Jonathan Freve [Address Omitted] Re: Retention Compensation Dear Jon:Retention Compensation Agreement • November 6th, 2023 • Galecto, Inc. • Pharmaceutical preparations • Massachusetts
As you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation as specified below, subject to this “Agreement”:
GALECTO, INC. SUPPORT AGREEMENTSupport Agreement • October 7th, 2024 • Galecto, Inc. • Pharmaceutical preparations • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of October 7, 2024 is made by and among Galecto, Inc., a Delaware corporation (“Buyer”), Bridge Medicines LLC, a Delaware limited liability company (the “Seller”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Buyer.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 10th, 2025 • Galecto, Inc. • Pharmaceutical preparations
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 12, 2025, is entered into by and among Galecto, Inc., a Delaware corporation (“Galecto”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among Galecto and the Investors party thereto, dated on or around the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
EMPLOYMENT CONTRACT December 2012Employment Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
ContractLease Agreement • August 5th, 2021 • Galecto, Inc. • Pharmaceutical preparations
English Summary of a lease agreement dated April 15, 2021 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and Symbion A/S (the “Landlord”)
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. BRIDGE MEDICINES LICENSE AGREEMENTLicense Agreement • March 19th, 2025 • Galecto, Inc. • Pharmaceutical preparations • New York
This BRIDGE MEDICINES LICENSE AGREEMENT (“Agreement”), dated as of January 31, 2020 (the “Effective Date”), is by and between The Rockefeller University, a New York not-for-profit corporation, with offices located at 1230 York Avenue, New York, NY 10065 (“Licensor”), and Bridge Medicines LLC, a Delaware limited liability company, with offices located at Lasdon House, Suite 514, 420 East 70th Street, New York, NY 10021 (“Bridge Medicines” and, in its role as a licensee hereunder, “Licensee”). The parties to this Agreement are collectively referred to as the “Parties” and individually as a “Party.”